Mar 07, 2024 / 01:30PM GMT
Operator
Good morning. My name is Kevin, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the EyePoint Pharmaceuticals' fourth quarter and full-year 2023 financial results and recent corporate developments conference call.
(Operator Instructions) Please be advised this call is being recorded at the company's request. I would now like turn the call over to George Elston, Executive Vice President and Chief Financial Officer of EyePoint Pharmaceuticals.
George Elston - EyePoint Pharmaceuticals Inc - Chief Financial Officer
Thank you and thank you all for joining us on today's conference call to discuss EyePoint Pharmaceuticals' fourth quarter and full-year 2023 financial results and recent corporate developments. With me today is Dr. Jay Duker, President and Chief Executive Officer. And Jay will begin with a review of recent corporate updates and discuss the ongoing clinical trials for EYP-1901. I will close with commentary on the fourth quarter and full-year 2023 financial results. We will then open the call for your
Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot